Karolinska Development announces Chairman Bo Jesper Hansen and CEO Jim Van heusden's decision to Step Down, and the promotion of Viktor Drvota to CEO
STOCKHOLM - APRIL 20, 2017.
Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that Bo Jesper Hansen, MD, PhD, Chairman of the Company's Board, has informed Karolinska Development's Nomination Committee that he will not stand for re-election at the 2017 Annual General Meeting. The Nomination Committee's proposals will be announced in a separate press release in connection with the notice of the 2017 Annual General Meeting which is due to take place on 24 May 2017.
Bo Jesper Hansen was appointed as Chairman in 2013. Under his chairmanship, he initiated the successful transformation of Karolinska Development from a wide-ranging collection of early stage science-driven projects into a highly focused investment company with a portfolio of business-driven companies capable of delivering significant shareholder value.
"Bo Jesper Hansen's broad industry and leadership experience has been crucial in guiding Karolinska Development through the most significant changes in the Company's history. We would like to thank him for his considerable efforts that have created a strong platform for Karolinska Development's future success." said Niclas Adler, chairman of the Nomination Committee of Karolinska Development.
Karolinska Development also announces that its CEO, Jim Van heusden, PhD, has tendered his resignation and will formally leave the Company at the end of October 2017.
"Jim Van heusden has done a remarkable job as the CEO of Karolinska Development. Under his leadership, he successfully executed a major strategic turn-around that has positioned the Company to become a leading Nordic life science investment company. Karolinska Development is now in an excellent shape, with its portfolio companies poised to deliver significant value generating milestones in the coming 12 - 18 months. With the strategic turn-around now complete we understand Jim's desire to look for new opportunities and wish him every success for the future," said Bo Jesper Hansen, Chairman of the Board of Karolinska Development.
"I would like to thank Bo Jesper Hansen and the Board for their unwavering support during the major strategic turn-around that we have implemented in the last two years. With these changes now finished I believe it is the appropriate time for me to look for a new challenge. I am very proud of what we have achieved together and am convinced Karolinska Development is now in a much stronger position to deliver value for all its stakeholders from its portfolio of exciting therapeutic and med-tech companies." says Jim Van heusden, CEO of Karolinska Development.
The Board of Directors is pleased to announce the promotion of Viktor Drvota MD PhD as the Company's Chief Executive Officer, effective June 1 2017. Dr Drvota is currently Karolinska Development's Deputy Chief Executive Officer and Chief Investment Officer.
Bo Jesper Hansen, Chairman of the Board of Karolinska Development says: "I am extremely pleased to announce Viktor's promotion to the role of CEO. Since joining the Company in early 2016, Viktor has made an important contribution to the strategic turnaround that we have implemented. With his significant life sciences investment experience, centered on the Nordic region, and his impressive track record, Viktor is the ideal person to lead Karolinska Development through the next phase of its development."
Dr Drvota joined Karolinska Development as Chief Investment Officer in February 2016 and was promoted Deputy Chief Executive Officer in March 2017. Dr Drvota brings more than 15 years of life science investment experience. Prior to joining Karolinska Development he worked at SEB Venture Capital, where he was Head of Life Science from 2002 and a senior investment manager. Before joining SEB, Viktor was a practicing cardiologist at Huddinge University Hospital in Stockholm. He has been an Associate Professor in Cardiology at Karolinska Institutet, Stockholm, since 2002.
Dr Drvota says: "I am thrilled to take on the role of CEO in addition to my current position as Chief Investment Officer. With the Company's strategic turnaround now complete, Karolinska Development is in excellent shape to deliver significant shareholder value as its portfolio companies deliver a number of important clinical and commercial milestones over the next 12 to 18 months."
For further information, please contact:
Jim Van heusden, CEO, Karolinska Development AB
Phone: +46 72 858 32 09, e-mail: email@example.com
Viktor Drvota, Chief Investment Officer and Deputy CEO, Karolinska Development AB
Phone: +46 73 982 52 02, e-mail: firstname.lastname@example.org
David Dible/Mark Swallow/Pip Batty, Citigate Dewe Rogerson
Phone: +44 20 7638 9571; e-mail: KDev@citigatedr.co.uk
TO THE EDITORS
About Karolinska Development AB
Karolinska Development AB (Nasdaq Stockholm: KDEV) is a Nordic life sciences investment company. The company focuses on identifying breakthrough medical innovations in the Nordic region that are developed by entrepreneurs and leadership teams. The Company invests in the creation and growth of companies that advance these assets into commercial products that are designed to make a difference to patients' lives while providing an attractive return on investment to shareholders.
Karolinska Development has access to world-class medical innovations at the Karolinska Institutet and other leading universities and research institutes in the Nordic region. The Company aims to build companies around scientists who are leaders in their fields, supported by experienced management teams and advisers, and co-funded by specialist international investors, to provide the greatest chance of success.
Karolinska Development has established a portfolio of nine companies targeting opportunities in innovative treatment for life-threatening or serious debilitating diseases.
The Company is led by an entrepreneurial team of investment professionals with a proven track record as company builders and with access to a strong global network.
For more information, please visit www.karolinskadevelopment.comThis information is information that Karolinska Development AB (publ) (Nasdaq Stockholm: KDEV) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of Jim Van heusden, at 08:00 am CEST on 20 April 2017.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Karolinska Development AB (publ) via Globenewswire
Följ NASDAQ OMX
Abonnera på våra pressmeddelanden.
Senaste pressmeddelandena från NASDAQ OMX
Integrum uppmärsammas av Frankrikes president Emmanuel Macron och Stefan Löfven17.11.2017 19:02 | Pressmeddelande
PRESSINFORMATION 17 november 2017 Integrum blev vid fredagens EU-toppmöte i Göteborg som ett av få inbjudna att presentera bolagets tankestyrda proteser för Frankrikes president Emmanuel Macron och Stefan Löfven. Detta i samband med det strategiska partnerskap för innovation mellan Frankrike och Sverige som undertecknades vid mötet med mål att presentera konkreta framsteg inom två år. Integrum var utvalt som ett bra exempel på innovativt företag som utvecklar avancerade medicintekniska produkter där samspelet mellan människa och teknik skapar stort värde för användaren. Under mötet med president Emmanuel Macron och Stefan Löfven demonstrerades Integrums världsunika proteser som styrs med hjälp av tankekraft. Tekniken möjliggör att personer kan få en protes direkt kopplat till skelett, nerver och muskler utan att ha elektroder tillfälligt fästa utanpå huden. "Det är självklart mycket hedrande att I
CrownBio Launches an Innovative Grant Program to Fund Advancements in Preclinical Oncology Research17.11.2017 18:07 | Pressmeddelande
SANTA CLARA, Calif., Nov. 17, 2017 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:ticker 6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, announces the launch of a grant program supporting oncology research scientists which provides funding for projects that show promise for scientific advancement of Patient Derived Xenograft (PDX) technology. Research Grants up to $50,000 will be awarded to projects focused on accelerating the pace of preclinical innovation and novel PDX methodologies that improve clinical predictions with sound science. The program offers an opportunity for investigators to receive funding for projects that may not receive support through traditional funding channels. Submitted proposals will be reviewed and selected by CrownBio's Scientific Steering Committee with the goa
Barings Backs Sentinel Capital Partners in Acquisition of Nekoosa17.11.2017 17:00 | Pressmeddelande
CHARLOTTE, N.C., Nov. 17, 2017 (GLOBE NEWSWIRE) -- Barings, one of the world's leading asset management firms, announced today that it served as Lead Agent on a senior secured credit facility to support Sentinel Capital Partners in its acquisition of Nekoosa ("Nekoosa" or the "Company"). Headquartered in Nekoosa, Wisconsin, the Company is a leading manufacturer of specialty paper and film products used in the graphics and commercial print markets, including application and pressure-sensitive tapes, specialty synthetic papers, sheeted digital and offset grade carbonless paper, and extruded film products. Nekoosa serves a highly diverse base of more than 70,000 commercial print and graphics shops in 65 countries. Barings served as lead senior lender on the transaction, which included a senior term loan and a revolving credit facility. "Sentinel is pleased to have Barings' support on our investment in Nekoosa," said Scott Perry, a partner with Sentinel Capital Partner
At SC17, ExaScaler and PEZY Computing Unveil Gyoukou Supercomputer with a High Combined Green500/Top500 Ranking16.11.2017 23:29 | Pressmeddelande
ExaScaler and PEZY Computing Also Take Top Three Green500 Positions DENVER, Nov. 16, 2017 (GLOBE NEWSWIRE) -- At SC17, ExaScaler and PEZY Computing unveiled their Gyoukou supercomputer whose Green500 and Top500 rankings attest to a unique combination of high efficiency and computing power. The Gyoukou supercomputer is installed at the Yokohama Research Institute in Japan. (Video: PEZY Liquid immersion cooling) PEZY supercomputers leverage 48V Factorized Power, a high efficiency, high density power distribution architecture. PEZY's CPUs are co-packaged with Vicor's Power-on-Package ("PoP") Modular Current Multipliers ("MCMs"), which enable efficient, direct 48V to sub-1V current multiplication at the XPU. ExaScaler and PEZY Computing also achieved the #1, #2 and #3 positions on the Green500. These supercomputer system installations also utilize 48V Factorized Power. Come see us at SC17 at Booth 633 where ExaScaler / PEZY Computing will be
ELS Educational Services, Inc. Launches New Vacation English Program Starting January 201816.11.2017 20:59 | Pressmeddelande
New York, New York, Nov. 16, 2017 (GLOBE NEWSWIRE) -- ELS Educational Services, Inc. - one of the leading language services providers worldwide - has launched a new vacation English language program, ELS Language Experience+, which is set to begin enrollment for January 2018. "Here at ELS, our students and their English language goals always come first, and we are proud to introduce ELS Language Experience+ as an exciting new addition to the many quality programs we offer them," said ELS Chief Operating Officer, Reiji Terasaka. "This conversation-oriented, flexible new vacation English program allows students to make the most of their English instruction while gaining an invaluable cultural experience at the same time." ELS Language Experience+ concentrates on everyday speaking, communication skills and discussion, within a flexible course structure (three or six hours of study per day). Courses offered include: Everyday English, Grammar in Action, D
Global SD-WAN Partnership between CallTower and Aryaka to Deliver High-Performance Cloud Communication Solutions to Global Enterprises16.11.2017 16:02 | Pressmeddelande
SAN MATEO, Calif., Nov. 16, 2017 (GLOBE NEWSWIRE) -- Aryaka, the leading global SD-WAN provider, today announced a new partnership with CallTower, an industry-leading unified communications and collaboration company, to provide global enterprise customers with fast and reliable, high-quality cloud service connectivity. CallTower's partnership with Aryaka will deliver improved performance of their unified communications solutions to global enterprise customers. CallTower has linked their data centers with the Aryaka global network to deliver secure, reliable connectivity with quality of service guarantees for mission critical real-time communication applications. CallTower Cisco and Microsoft unified communications solutions, including Cloud Contact Center customers will now be able to add Aryaka's global SD-WAN service to further optimize, and enhance reliability over a secure network. "In addition to our unified communications offering, we have seen tremendous growth i
I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.Besök vårt pressrum